ZyVersa is a biopharmaceutical company developing first-in-class products for the treatment of renal and inflammatory diseases.
WESTON, Fla. and BRIDGEWATER, NJ, December 12, 2022 /PRNewswire/ – ZyVersa Therapeutics, Inc. : LSPR or “Larkspur”), a special purpose space exploration acquisition company, is pleased to announce the closing of their previously announced business combination.
(PRNewsfoto/Variant Pharmaceuticals, Inc.)
Larkspur dealers approved the business combination and related transactions at a special meeting and December 8, 2022. The combined company will operate as ZyVersa Therapeutics, Inc., under the previous ZyVersa management team, led by senior executives. Stephen C. GloverCo-founder, Chief Executive Officer, and President of ZyVersa. Daniel J. O’Connor, who is president and CEO of Larkspur, will join the Board of Directors of ZyVersa. ZyVersa stock is expected to begin trading on the Nasdaq under the symbol “ZVSA”. December 13, 2022. Larkspur warrants previously traded under the symbol “LSPRW” will no longer be listed for trading on the Nasdaq.
“Today is an important day for ZyVersa. We are pleased to close our business relationship with Larkspur and begin the next chapter as a publicly traded company,” said Mr. Glover said. “I would like to thank our partners in Larkspur, our company leaders, and my colleagues at ZyVersa who have contributed to this achievement. The proceeds from this transaction allow ZyVersa to take action to improve the housing program. Our drug for VAR 200, a cholesterol efflux mediator. for patients with kidney disease, as well as the continuation of IC 100, an inhibitor of inflammatory ASC, is exploring new drug applications,” Mr. Glover continued.
“We are pleased to be working with ZyVersa on this transaction,” said Mr. O’Connor. “We believe that ZyVersa has the potential to build retail value, based on its unique value proposition as discussed in the public filing,” Mr. O’Connor continued.
Counselors
Benchmark LLC and Noble Capital Markets, Inc. are serving as financial advisors to ZyVersa, Lowenstein Sandler LLP is also serving as legal advisor to ZyVersa.
AGP/Alliance Global Partners, of which Manatt, Phelps & Phillips, LLP is serving as legal advisor, is serving as financial advisor to Larkspur. Alston & Bird LLP is serving as legal counsel in Larkspur.
History of Larkspur Health Acquisition Corp.
Larkspur is a Special Purpose Corporation (SPAC) formed to identify biopharmaceutical companies that can grow and thrive as newly formed public companies, and benefit from Larkspur’s expertise and capital investment. Larkspur’s management team and board of directors have included former management teams and senior executives of private and/or public biopharmaceutical companies and have over 50+ years of combined financial and operational experience. The group strongly believes in the growth opportunities in the biotechnology industry. They are experienced professionals looking to connect with innovators and thinkers in the biopharmaceutical sector. Their marketing approach supports management teams in making impactful decisions that focus on growth and optimal performance. For more information, please visit www.lsprhealth.com.
History of ZyVersa Therapeutics, Inc.
ZyVersa is a clinical specialty biopharmaceutical company that leverages advanced technology, independent to develop product candidates that meet high medical needs in the areas of renal disease and inflammation. ZyVersa’s development pipeline includes the Phase 2a-ready VAR 200, a cholesterol efflux mediator for the treatment of rare kidney disease, with a focus on glomerulosclerosis. ZyVersa believes that VAR 200 can treat other glomerular diseases, including Alport’s disease and diabetic kidney disease. ZyVersa’s development pipeline also includes IC 100, an anti-inflammatory ASC drug developed to treat several inflammatory diseases. For more information, please visit www.zyversa.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this prospectus that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include disclosures. regarding management’s intentions, plans, beliefs, expectations, or forecasts for the future, therefore, you are cautioned not to place undue reliance on them. No forward-looking statements are guaranteed, and actual results may differ materially from those anticipated. ZyVersa Therapeutics, Inc. (“ZyVersa”) uses words such as “anticipate,” “believe,” “plan,” “anticipate,” “project,” “future,” “intend,” “potential, “”able,” “”should,” “could,” “plan,” “forecast,” “could,” “continue,” “guide,” and similar words to identify these words and – Forward-looking statements are intended to be covered by port provisions. Such forward-looking statements are based on ZyVersa’s expectations and involve risks and uncertainties; Because therefore, actual results may differ materially from those expressed or implied due to a number of factors, including ZyVersa’s plans to develop and commercialize its products, the timing of ZyVersa’s planned preclinical and domestic drugs; the timing of data availability from ZyVersa’s preclinical and clinical trials; the timing of any approved new drugs or new drug applications; ZyVersa’s plans to research, develop and commercialize its current and future products ; clinical efficacy, potential benefit and acceptance of ZyVersa product candidates; Zy Versa’s business, marketing and manufacturing capabilities and strategies; ZyVersa’s ability to protect its intellectual property; and ZyVersa’s plans for future revenues, expenses, capital requirements and the need for additional financing.
New matters may arise from time to time, but it is not possible for ZyVersa to predict all such matters, nor can ZyVersa evaluate the effect of any such matter on the business or the extent to which it any, or a combination of things can. cause actual results to differ materially from those contained in any forward-looking statement. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
The release of this newsletter does not constitute an offer to sell, or a solicitation to buy, any security.
History of ZyVersa Therapeutics, Inc.
